AngioDynamics Reports Q1 2027 Earnings: MedTech Segment Drives Growth
AngioDynamics (ANGO) reported first-quarter financial results for fiscal year 2027, showing strong performance in its medtech segment. Total net sales reached $80.9 million, a 6.9% increase from the prior year. The MedTech Segment revenue grew by 13.2%, reaching $39.9 million and now representing nearly half of total company revenue. Key product lines showed mixed results: Auryon saw double-digit growth for its 21st consecutive quarter, while NanoKnife experienced a strong increase in sales due to demand from prostate procedures. However, AngioVac faced a year-over-year decline despite sequential improvement. Gross margin improved significantly on both GAAP and adjusted bases, driven by favorable pricing and product mix. The company maintained an adjusted net loss of $1.8 million or $0.04 per share but reported more than double the Adjusted EBITDA compared to last year's first quarter. AngioDynamics also provided full-year guidance with revenue expected between $336 million and $341 million, along with MedTech growth projected at 12%–15%. Risks include macroeconomic pressures and variability in capital equipment sales.
Tickers: $ANGO
Topics: financial_performance revenue_growth segment_analysis